Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis

Authors

  • Joana Simões University of Porto, Centro Hospitalar de São João, Department of Oncology
  • Isabel Augusto University of Porto, Centro Hospitalar de São João, Department of Oncology
  • Sara Meireles University of Porto, Centro Hospitalar de São João, Department of Oncology
  • Lurdes Vendeira University of Porto, Centro Hospitalar de São João, Department of Urology
  • Carlos Silva University of Porto, Centro Hospitalar de São João, Department of Radiation Oncology

DOI:

https://doi.org/10.4322/acr.2018.011

Keywords:

Prostate cancer, Dialysis, Docetaxel, Enzalutamide, Radium-223.

Abstract

At a time when the population shows increasing longevity, entities such as cancer and chronic kidney disease (CKD) are more frequently connected. In the United States, approximately 6% of the patients on hemodialysis have cancer. The challenge to manage oncologic patients with CKD in a hemodialytic program represents a great shortage of available information on the choice of the best drug, timing, dosage adjustments, dialysis method, and treatment safety. We present the case of a patient with prostate cancer and terminal CKD in hemodialysis, and the treatment sequence after the development of resistance to hormonal blockade therapy, which included docetaxel, enzalutamide, and radium-223.

Downloads

Download data is not yet available.

Downloads

Published

2018-06-13

How to Cite

Simões, J., Augusto, I., Meireles, S., Vendeira, L., & Silva, C. (2018). Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis. Autopsy and Case Reports, 8(2), e2018011. https://doi.org/10.4322/acr.2018.011

Issue

Section

Article / Clinical Case Report